| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Lycia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $277.05M | Series D | 6/10/2026 | $75M | $388.52M | $2.04 | Janus Henderson Investors, Balyasny Asset Management, Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly and Company, Franklin Templeton, Invus, RTW Investments, Venrock | ||||
 | Marea | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $190M | Series B | 6/18/2024 | $152.89M | $267.31M | $1.45 | Sofinnova Investments, Forbion Capital Partners, Perceptive Advisors, venBio, Alpha Wave Global, Omega Funds, Citadel, Third Rock Ventures | ||||
 | Nabla Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $107.26M | Series B | 5/15/2026 | $70.12M | $476.82M | $47.41 | Undisclosed Investors | ||||
 | Synthekine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $396.11M | Series D | 10/20/2025 | $107.5M | $271.61M | $0.97 | Undisclosed Investors | ||||
 | A2 Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $287.63M | Series C | 1/9/2025 | $80M | $274.56M | $0.74 | The Column Group, Samsara BioCapital | ||||
 | AiTA | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $25.63M | Series C | 1/14/2025 | $10M | $317.19M | $5.05 | Undisclosed Investors | ||||
 | Clear Labs | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $157.08M | Series D | 1/13/2025 | $30M | $395.17M | $2.80 | Counterpoint Global, Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, T. Rowe Price Associates | ||||
 | Flare Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $290.35M | Series C | 6/30/2026 | $85M | $188.49M | $0.37 | Third Rock Ventures, Nextech Invest, Pfizer, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, Eventide Asset Management | ||||
 | Ossium Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $35.91M | Series D | 1/27/2026 | $31.31M | $46.46M | $0.23 | Undisclosed Investors | ||||
 | Pendulum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.76M | Series C | 6/30/2023 | $64M | $308.05M | $3.24 | Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, Fonterra | ||||
 | Syncromune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.01M | Series A-1 | 8/21/2025 | $99.85M | $254.93M | $3.43 | Wasatch Equity Partners | ||||
 | Verge Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $167.53M | Series C* | 9/8/2023 | $42M | $403.75M | $7.19 | Alexion, AstraZeneca, Alumni Ventures, Tenmile | ||||
 | Aardvark Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $129.13M | Series C | 5/9/2024 | $85M | $267.58M | $1.77 | Decheng Capital, Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Ventures, Silver Arc Private Capital, Prader-Willi Syndrome Association, Vickers Venture Partners, Foundation for Prader-Willi Research | ||||
 | Biolinq | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $275.18M | Series C-1 | 4/22/2025 | $100M | $397.31M | $1.05 | Alpha Wave Ventures, RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, Features Capital | ||||
 | ElectraDx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $46.77M | Series B | 11/14/2025 | $32M | $270.54M | $7.31K | TAUNS Laboratories | ||||
 | Gameto | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $117M | Series C | 8/12/2025 | $44M | $234.3M | $7.31 | Overwater Ventures, Insight Partners, RA Capital, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group, Pontiva Healthcare Partners, Portfolia | ||||
 | Obsidian Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $329.03M | Series C | 4/3/2024 | $160.5M | $480.83M | $1.90 | Wellington Management, Foresite Capital, Janus Henderson Investors, Novo Holdings, Paradigm BioCapital, RTW Investments, T. Rowe Price Associates, Woodline Partners, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCG Crossover Management, Samsara, Surveyor Capital | ||||
 | Vedanta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.86M | Series B-1 | 8/6/2026 | $22.57M | $113.87M | $0.17 | AMR Action Fund, BNP Paribas | ||||
 | Ansa Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $57.42M | Series B Plus | 10/1/2025 | $24.28M | $260.65M | $0.35 | Cerberus Ventures, Blue Water Life Science Advisors, Altitude Life Science Ventures, Fall Line Capital, AIM13, Black Opal Ventures | ||||
 | Detect | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $77.02M | Series A-1 | 7/29/2026 | $31.99M | $118.22M | $1.22 | Undisclosed Investors | ||||
 | Engrail Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $215.08M | Series B-4 | 4/7/2025 | $10M | $275.98M | $1.06 | Undisclosed Investors | ||||
 | Epic Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $606.66M | Series A-3 | 12/29/2023 | $20.9M | $94.14M | $3.00 | Undisclosed Investors | ||||
 | Kallyope | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $573.45M | Series E | 8/31/2026 | $93.99M | $290.16M | $0.79 | Undisclosed Investors | ||||
 | SetPoint Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $303.01M | Series D | 8/11/2025 | $115M | $471.62M | $1.51 | Elevage Medical Technologies, Ally Bridge Group, Northwell Health, SPRIG Equity, Norwest Venture Partners, New Enterprise Associates, Viking Global Investors, Action Potential Venture Capital, Abbott, Boston Scientific, Euclidean Capital, Richard King Mellon Foundation, Morgenthaler Ventures, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Gilmartin Capital, Midas Capital | ||||